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Antidiabetic, antioxidative, and antihyperlipidemic activities of aqueous-methanolic (2:3) extract of Swietenia mahagoni (L.)
Jacq. (family Meliaceae) seed studied in streptozotocin-induced diabetic rats. Feeding with seed extract (25mg 0.25mL distilled
water−1100gm b.w.−1rat−1 day
−1) for 21 days to diabetic rat lowered the blood glucose level as well as the glycogen level in liver.
Moreover, activities of antioxidant enzymes like catalase, peroxidase, and levels of the products of free radicals like conjugated
diene and thiobarbituric acid reactive substances in liver, kidney, and skeletal muscles were corrected towards the control after this
extract treatment in this model. Furthermore, the seed extract corrected the levels of serum urea, uric acid, creatinine, cholesterol,
triglyceride,andlipoproteinstowardsthecontrollevelinthisexperimentaldiabeticmodel.Theresultsindicatedthepotentialityof
the extract of S. mahagoni seed for the correction of diabetes and its related complications like oxidative stress and hyperlipidemia.
Theextractmaybeagoodcandidatefordevelopingasafety,tolerable,andpromisingneutraceuticaltreatmentforthemanagement
of diabetes.
1.Introduction
Diabetes mellitus is a multifarious group of symptoms
characterized by hyperglycemia, abnormal lipid and protein
metabolism, along with speciﬁc long-term complications
aﬀecting the retina, the kidney, and the nervous system
mainly [1]. Consumption of calorie-rich diet, obesity, and
sedentary life style have lead to tremendous increase in
the number of diabetics worldwide especially in Asia [2].
Many oral hypoglycaemic agents, such as sulfonylurea and
biguanides, are available along with insulin for the treatment
of diabetes mellitus, but these agents have signiﬁcant side
eﬀects [3], and some are ineﬀective in chronic diabetic
patients [4]. Thus, there is an increasing demand of new
antidiabetic natural products especially neutraceuticals with
lesser side eﬀects and high antidiabetic potential.
In this context, worldwide eﬀorts have been taken to
improve plant-based therapies [5]. WHO [6] recommended
for the assessment of traditional medicinal plant in con-
nection with the management of diabetes mellitus [7–9].
Currently, several hundred plants have been reported to
have beneﬁcial eﬀects for the treatment of diabetes mellitus,
and we have several reports in this line [10–12]a sw e l la s
of others [13–15]. Research on phytomolecules as diabetic
remedies is upraising gradually as these are with minimal or
no side eﬀects [16–18]. Swietenia mahagoni (S. mahagoni),
is under family Meliaceae, beautiful, lofty, evergreen, large
native tree of tropical America, Mexico, South America,
and India. Usually, this plant is 30−40 meters in height and
3-4 meters in girth [19]. The seeds of S. mahagoni have
been reported for its anti-inﬂammatory, antimutagenecity,
and antitumour activities [20]. In Indonesia and in India,2 Evidence-Based Complementary and Alternative Medicine
S. mahagoni seed used as folk medicine to cure diabetes
[21]. There is no systematic work about the antidiabetic
activity of S. mahagoni though there are very few infor-
mations of this plant in this line [22, 23]. The present
study was therefore carried out to evaluate the traditional
used of S. mahagoni as antidiabetic scientiﬁcally. Further-
more, the positive roles of natural products (neutraceuti-
cals) for the correction of oxidative stress and hyperlipi-
daemia, which are diabetes-related complications, were also
assessed.
2.MaterialsandMethods
2.1. Preparation of Seed Extract. Swietenia mahagoni seeds
were collected from Midnapore, District Paschim Midna-
pore,WestBengal,India,inthemonthofDecemberandwere
identiﬁed by taxonomist of Botany Department, Vidyasagar
University, Midnapore. A voucher specimen was submitted
in the Department of Botany, Vidyasagar University and
numbered as Swietenia mahagoni (L.) Jacq./VU/01/09.
Seeds were dried in an incubator for 2 days at 40◦C,
crushed in an electric grinder, and then pulverized. Out
of this powder, 50g was suspended in the mixture solvent
consisting of 80mL of water and 120mL methanol and the
mixture was kept in an incubator at 37◦C for 36 hours. The
mixture was stirred intermittently for a 4-hours interval. The
mixture was then ﬁltered and ﬁltrate was dried under low
pressure and low temperature using rotary evaporator ﬁtted
with vacuum pump. Finally, 3.2gm of powder was collected.
Thiswasdiscoveredindistilledwaterinaﬁxeddoseandused
for the treatment.
2.2. Chemicals. Streptozotocin (STZ) was obtained from
Sigma (USA). All other chemicals used here were of analyti-
cal grade obtained from E. Merck, Mumbai, and HIMEDIA,
Mumbai, India or purchased from Sigma-Aldrich Diagnostic
Ltd. USA. Kits for diﬀerent enzyme assay were purchased
from Crest Biosystems, Goa, India.
2.3. Selection of Animal and Animal Care. Twenty four
matured normoglycemic (having fasting blood glucose level
80−90mg/dL) Wistar strain male albino rats, 3 months
of age, weighing about 120 ± 10g were selected for this
experiment. Animals were acclimated for a period of 15 days
in our laboratory condition prior to the experiment. Rats
were housed at an ambient temperature of 25 ± 2◦Cw i t h
12 hours light:12 hours dark cycle. Rats were fed pellet diet
and water ad libitum. The principle of Laboratory Animal
Care and instructions given by our Institutional Ethical
Committee were followed throughout the experiment.
2.4. Induction of Diabetes in Rats. Twenty-four hours fasted
eighteen rats out of twenty four were subjected to a single
intramuscular injection of STZ (4mg 100−1 b.w) in 0.1mL
of citrate buﬀer (pH = 4.5) 100g−1,b . w . −1rat−1.A f t e r7d a y s
of STZ injection, diabetic rats (fasting blood glucose level
>250mg/dL <350mg/dL) were selected for the study.
2.5. Animal Treatment. Twelve diabetic rats having said
criteria were selected. Six rats were categorized into dia-
betic control and the rest of rats were placed in extract
administered diabetic group. Other six normoglycemic rats
were considered under control group. Extract treatment of S.
mahagoni seed was started from the 7th day of postinjection
period of STZ and was considered as 1st day of experiment.
T h et r e a t m e n tw a sc o n t i n u e df o rn e x t2 1d a y s .
Group I (control group). Rats of this group received
single intramuscular injection of citrate buﬀer (0.1mL
100g−1 b.w.−1) at the time of STZ injection to the other
animals for diabetic induction.
Group II (diabetic control group). Diabetic rats of this
group were forcefully fed with water at a dose of 0.25mL of
distilled water 100g b.w−1day−1 for 21 days by gavage.
Group III (extract administered diabetic group). Dia-
betic rats of this group were forcefully fed with aqueous-
methanolic (2:3) extract of S. mahagoni seed at a dose
of 25mg 0.25mL water−1100g b.w.−1day−1 for 21 days at
fasting state by gavage.
Extract administration to the rats of group III was
performed early in the morning and at fasting state by
gavage. Animals of the control group (Group I) were
subjected to gavage of distilled water like group II for 21
days at the time of extract treatment to the animals of group
III to keep all the animals under the same experimental
condition and stress imposition if any due to treatment of
extractandanimalhandling.Startingfromﬁrstdayofextract
treatment to diabetic rats, fasting blood glucose levels (12
hours after feed delivery) in all the groups were measured
by single touch glucometer on every 7-day interval. On
the 21st day of experiment, blood was collected from the
tail vein, and fasting glucose level was monitored by single
touch glucometer. All the animals were sacriﬁced at fasting
state by light ether anesthesia followed by decapitation
after recording the ﬁnal body weight. Blood was collected
from the dorsal aorta by a syringe and the serum was
separated by centrifugation at 5000rpm for 5 minutes for
the estimation of serum toxicity study. The liver, kidney,
and skeletal muscles were dissected out and stored at −20◦C
for the quantiﬁcation of glycogen, for the assessment of the
activities of the antoxidant enzymes—catalase (CAT) and
peroxidase (Px), and for the quantiﬁcation of the levels of
the products of free radicals like conjugated diene (CD)
and thiobarbituric acid (TBARS). Assessment of protein
metabolic and lipid metabolic disorders was also performed
by the measurement of the levels of serum urea, uric acid,
creatinine, total cholesterol, triglyceride, high density, and
low-density and very low-density lipoprotein cholesterol.
2.6. Estimation of Glycogen Level. Hepatic glycogen level was
measured according to the standard protocol [24]. In brief,
hepatic tissues was homogenized in hot ethanol (80%) at a
tissue concentration of 100mgmL−1 and then centrifuged
at 9500rpm for 20 minutes. The residue was collected,
dried over a water bath, and then extracted at 0◦Cf o r2 0
minutes by adding a mixture of 5mL water and 6mL of
52% perchloric acid. The collected material was centrifugedEvidence-Based Complementary and Alternative Medicine 3
at 9500rpm for 15 minutes for recovery of the supernatant.
From the recovered part, 0.2mL supernatant was transferred
in graduated test tube and made to 1mL volume by the
addition of distilled water. Graded standards were prepared
using 0.1, 0.2, 0.4, 0.6, 0.8, and 1.0mL of a working standard
solution, and volume of all each standard solution was made
to 1mL using distilled water. Anthrone reagent (4mL) was
added to all the test tubes and the tubes, were then heated
in a boiling water bath for 8 minutes, allowed to cool at
room temperature, and the intensity of the green to dark
green color of the solution was recorded at 630nm. Glycogen
content of the sample was determined from a standard curve
prepared with standard glucose solution.
2.7. Biochemical Assay of Antioxidant Enzymes. The activities
ofcatalaseoftheliver,kidney,andskeletalmusclesweremea-
suredbiochemically[25].Fortheevaluationofcatalaseactiv-
ity, target organ of each animal was homogenized separately
in 0.05M Tris-HCl buﬀer solution (pH-7.0) at the tissue
concentration of 50mgmL−1. These homogenized samples
were centrifuged at 10,000rpm at 4◦Cf o r1 0m i n u t e s .
In spectrophotometric cuvette, 0.5mL of 0.00035MH2O2
and 2.5mL of distilled water were mixed and reading of
absorbance was noted at 240nm. Supernatant of sample was
added at a volume of 40μL and the subsequent six readings
were noted at 30-second interval.
The peroxidase activity was measured in the above-said
tissues, according to the standard method [26]. The samples
were homogenized in ice-cold of 0.1M phosphate buﬀer
saline (pH-7.0) at the tissue concentration of 50mg mL−1.
Next, 20mM guiacol was mixed with 0.1mL supernatant
collected from the homogenate. In presence of 0.3mL of
12.3mMH2O2, the time was recorded for an increase in the
absorbance by 0.1 at 436nm.
2.8. Measurement of Protein Metabolic Disorders
2.8.1. Serum Urea, Uric acid, and Creatinine. Levels of
serum urea, uric acid, and creatinine were measured using
kits from Merck Diagnostic Ltd, India [27–29], following
spectrometric methods. The values were expressed in mg
dL−1 in all the cases.
2.9. Measurement of Lipid Metabolic Disorders
2.9.1. Serum Total Cholesterol (TC), Lipoprotein Cholesterol,
and Triglyceride (TG). Serum TC was quantiﬁed spec-
trophotometrically [30] by the addition of enzyme present
in the reagent kit (Span Diagnostic Ltd, Surat, India). The
absorbance of red quinoneimine complex was determined at
505nm. The value of TC present in serum was expressed in
mg dL−1.
Levels of serum low-density lipoprotein cholesterol
(LDLc) and very low-density lipoprotein cholesterol
(VLDLc) were measured according to a standard protocol
[31]. High-density lipoprotein cholesterol (HDLc) level was
measured biochemically [32].
Serum TG level was measured by using a kit from Span
Diagnostics Pvt. Ltd, Boroda, India. The absorbance was
measured at 520nm. The value was expressed in mg dL−1
[33].
2.10. Quantiﬁcation of Lipid Peroxidation from Concentra-
tion of Thiobarbituric Acid Reactive Substance (TBARS)
and Conjugated Diene (CD) in Liver, Kidney, and Skeletal
Muscles. The above mentioned tissues were homogenized
separatelyattheconcentrationof50mgmL−1 in0.1Mofice-
cold phosphate buﬀer (pH-7.4) and the homogenates were
centrifugedat10,000rpmat4◦Cfor5 minindividually. Each
supernatant was used for the estimation of TBARS and CD
levels. For the quantiﬁcation of TBARS, the homogenized
mixture of 0.5mL was mixed with 0.5mL of normal saline
(0.9g % NaCl) and 2mL of TBA-TCA mixture (0.392g
thiobarbituric acid in 75mL of 0.25N HCl with 15g
trichloroacetic acid). The volume of the mixture was made
up to 100mL by 95% ethanol and boiled at 100◦Cf o r1 0
minutes. This mixture was then cooled at room temperature
and centrifuged at 4000rpm for 10 minutes. The whole
supernatant was taken in spectrophotometer cuvette, and
absorbance was read at 535nm [34]. Quantiﬁcation of the
CD was performed by a standard method [35]. In brief, the
lipids from the homogenate were extracted with chloroform-
methanol (2:1) mixture followed by centrifugation at 1000
rpm for 5 min. The chloroform layer was evaporated to
dryness under a stream of nitrogen. The lipid residue was
dissolved in 1.5mL of cyclohexane and the absorbance was
noted at 233nm to measure the amount of hydroperoxide
formed.
2.11. Statistical Analysis. Analysis of variance (ANOVA)
followed by multiple comparison two-tail “t”t e s tw a su s e d
for statistical analysis of collected data [36]. Diﬀerences
were considered signiﬁcant at P<. 05. All the values were
indicated in the ﬁgures as Mean ± S.E.M (Standard Error of
Mean).
3. Results
3.1.BloodGlucoseLevel. DiabetesinducedbySTZresultedin
a signiﬁcant elevation in blood glucose level in comparison
to the control group. After administration of aqueous-
methanolic (2:3) extract of S. mahagoni seed to the diabetic
animals for 21 days, a signiﬁcant reduction in blood glucose
level was noted which was close to the control level (Table 1).
3.2. Hepatic Glycogen Level. Hepatic glycogen content was
decreased in the diabetic control group in comparison with
the control group. After treatment of this herbal extract to
the diabetic animals, there was a signiﬁcant recovery in the
glycogen content towards the control level (Figure 1).
3.3. Activities of CAT and Px. Activities of CAT and Px in
liver, kidney, and skeletal muscles were decreased signiﬁ-
cantly in diabetic control group with respect to the control
group. After the treatment of aqueous-methanolic (2:3)4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of aqueous-methanol extract of S. mahagoni seed on fasting blood glucose level in streptozotocin-induced diabetic male
albino rat.
Group Fasting blood glucose level (mg/dL)
0d a y 1st day 8th day 15th day 22nd day 29th day
(Day of STZ
administration)
(2nd day of
extract
treatment)
(21st day of
extract
treatment)
Control group 73.58 ±5.2a 74.72 ±4.8a 73.86 ±4.9a 74.34 ±4.7a 73.79 ±4.6a 73.88 ±4.7a
Diabetic group 75.64 ±4.9a 295.21 ±5.2b 318.32 ±5.8b 325.54 ±6.2b 317.00 ±5.9b 322.52 ±6.5b
Administered group 73.61 ±5.1a 297.52 ±4.5b 221.50 ±4.8c 172.67 ±5.2c 109.61 ±5.3c 76.26 ±4.9a
Data are expressed as Mean ± S.E.M; n = 6. ANOVA followed by multiple comparison two tail “t” test. Values with superscripts (a,b,c) in each vertical column
diﬀer from each other signiﬁcantly, P<. 05.
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Figure 1: Correction of glycogen content in hepatic tissue after
administration of aqueous-methanolic extract of S. mahagoni seed
in STZ-induced diabetic male albino rat. Each bar represents Mean
± S.E.M; n = 6. ANOVA followed by multiple comparison two tail
“t”test. Barsdiagrams withdiﬀerent superscripts (a,b,c) diﬀer from
each other signiﬁcantly, P<. 05.
extract of S. mahagoni seed to STZ-induced diabetic rat, the
levels of above enzyme activities were resettled towards the
control level (Figures 2 and 3).
3.4. Serum Urea, Uric acid, and Creatinine Levels. Serum
urea, uric acid, and creatinine levels were increased signif-
icantly in the diabetic control group with respect to the
control group. The levels of these parameters were restored
towards the control level after administration of aqueous-
methanolic extract of the seeds of S. mahagoni to the diabetic
rat (Figure 4).
3.5. Serum Lipid Proﬁle. Serum total cholesterol (TC) and
triglyceride (TG) levels were signiﬁcantly elevated in the
diabeticcontrolgroupincomparisonwiththecontrolgroup.
After treatment with the above-mentioned extract to the
diabetic animals, serum TC and TG levels were recovered
signiﬁcantly towards the control level (Figure 5).
Other parameters of this lipid proﬁle like serum LDLc
and VLDLc levels were elevated and serum HDLc level
was decreased in the diabetic control group in respect to
the control. The levels of the above-mentioned parameters
were recovered signiﬁcantly towards the control group after
treatment of the extract of S. mahagoni seed when compare
with the diabetic control group (Figure 6).
3.6. Levels of CD and TBARS. Levels of CD and TBARS in
liver,kidney,andskeletalmuscleswereincreasedsigniﬁcantly
in the diabetic control group when compared to the control
group. Signiﬁcant recovery was noted in the levels of the
above-mentioned parameters in liver, kidney and skeletal
muscles after administration of the seed extract to the
diabetic animal (Figures 7 and 8).
4. Discussion
The present study focuses the antidiabetic, antihyperlipi-
demic, and antioxidative capacities, as well as protein
metabolic disorders management eﬃcacy of the aqueous-
methanolic extract (2:3) of S. mahagoni seed in STZ-
induced diabetic male albino rat. The pilot studies focused
on the fact that the aqueous-methanol (2:3) extract was
the most eﬀective studied here out of the other extracts,
for the correction of above said disorders in STZ-induced
diabetic rat. Here, metabolic disorders in STZ-induced
diabetic rat have been established by the levels of blood
glucose, hepatic glycogen, serum urea, uric acid, creatinine,
cholesterol, triglyceride, and lipoproteins. These results are
in the same line of our previous studies [10–12, 37]a n do f
others [38, 39]. Oxidative stress developed in diabetic state isEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Resettlement in the activities of peroxidase in kidney, liver, and skeletal muscles after administration of aqueous-methanolic
extract of S. mahagoni seed in STZ-induced diabetic male albino rat. Bar expressed as Mean ± S.E.M; n = 6. ANOVA followed by multiple
comparison two-tail “t”-test. Bars with diﬀerent superscripts (a,b,c) diﬀer from each other signiﬁcantly, P<. 05.
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Figure 3: Eﬀect of aqueous-methanolic extract of S. mahagoni seed on the activities of catalase in kidney, liver, and skeletal muscles in STZ-
induced diabetic male albino rat. Bar represents Mean ± S.E.M; n = 6. ANOVA followed by multiple comparison two-tail “t”-test. Bars with
diﬀerent superscripts (a,b,c) diﬀer from each other signiﬁcantly, P<. 05.
inparalleltoourpreviousreportsandalsoinagreementwith
others [11, 12, 40–43]. Oxidative stress in diabetic model
has been focused here by the assessment of CAT and Px
activities in liver, kidney, and skeletal muscles, important
biosensors for oxidative stress assessment [44, 45]. Diabetes-
induced oxidative stress has been conﬁrmed here by the
elevation in the levels of end products of free radicals, that
is, TBARS and CD, indicators of oxidative injury [46, 47].
Diabetes-associated oxidative stress is developed by many
b i o c h e m i c a lp a t h w a y ss u c ha sg l u c o s ea u t o x i d a t i o n ,p r o t e i n
glycation, and so forth [48]. In diabetes, protein catabolism
isincreasedduetodeﬁciencyofcarbohydrate-derivedenergy
in connection with low-serum insulin [49]. This has been
indicated here by high levels of serum urea, uric acid, and6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Correction in the levels of urea, uric acid, and creatinine in serum after administration of aqueous-methanolic extract of S.
mahagoni seed in STZ-induced diabetic male albino rat. Bar represents Mean ± S.E.M; n = 6. ANOVA followed by multiple comparison
two-tail ‘‘t”-test. Bars with diﬀerent superscripts (a,b,c) diﬀer from each other signiﬁcantly, P<. 05.
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Figure 5: Correction in the levels of total cholesterol and triglyc-
eride in serum after treatment of aqueous-methanolic extract of S.
mahagoni seed in STZ-induced diabetic male albino rat. Bar are
expressed as Mean ± S.E.M; n = 6. ANOVA followed by multiple
comparisontwo-tail“t”-test.Barswithdiﬀerentsuperscripts(a,b,c)
diﬀer from each other signiﬁcantly, P<. 05.
creatinine. High-serum creatinine level is also the marker of
muscle wastage [50]. All these metabolic disorders in STZ-
induced diabetic rat were represented here by line diagram
(Figure 9(a)). Glycemic controlling capacity of the extract
in STZ induced diabetic state has been supported here by
the correction of blood glucose, and glycogen content in
liver, important sensors in this concern [51]. The above-
mantioned correction may be due to insulin mimetic action
of the above-mantioned extract as insulin is one of the
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Figure 6: Eﬀect of aqueous-methanolic extract of S. mahagoni
seed on serum high density lipoprotein cholesterol (HDLc),
low density lipoprotein cholesterol (LDLc) and very low density
lipoprotein cholesterol (VLDLc) levels in STZ-induced diabetic rat.
Bar represents Mean ± S.E.M; n = 6. ANOVA followed by multiple
comparisontwo-tail“t”-test.Barswithdiﬀerentsuperscripts(a,b,c)
diﬀer from each other signiﬁcantly, P<. 05.
important regulators of glycogen synthesis [52]. Correction
of oxidative injury which is associated with diabetes [53]
is another possibility of the recovery in glycemic disorders.
The plant extract was able to recover the protein metabolic
disorders possibly by stimulating the existing βcells and or
by regenerating βcells like other plant products which have
been claimed by us [40]a sw e l la sb yo t h e r s[ 15, 51].
Hyperlipidemia is associated with diabetic state [54]a n d
this may be due to uninhibited action of lipase [55]. High
levels of serum cholesterol, triglyceride, LDLc, and VLDLc
along with low level of serum HDLc in STZ-induced diabetic
statefocusedthelowlevelofseruminsulinandtheresultsare
consistence to our previous ﬁndings [11] and of others [56].
Since insulin inhibits adipose tissue hormone sensitive lipaseEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: Eﬀect of aqueous-methanolic extract of S. mahagoni seed on the levels of conjugated diene (CD) in kidney, liver, and skeletal
muscles in STZ-induced diabetic male albino rat. Bar represents Mean ± S.E.M; n = 6. ANOVA followed by multiple comparison two-tail
“t”-test. Bars with diﬀerent superscripts (a,b,c) diﬀer from each other signiﬁcantly, P<. 05.
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Figure 8: Correction in the levels of thio-barbituric acid reactive substances (TBARS) in kidney, liver, and skeletal muscles after
administration of aqueous-methanolic seed extract of S. mahagoni in STZ-induced diabetic male albino rat. Values expressed as Mean ±
S.E.M; n = 6. ANOVA followed by multiple comparison two-tail “t”-test. Bars with diﬀerent superscripts (a,b,c) diﬀer from each other
signiﬁcantly, P<. 05.
and reduces lipolysis, the aqueous-methanolic extract of S.
mahagoni seed may correct the above mantioned disorders
by mimicking insulin action. The most exciting results and
the additional advantage of this extract over the existing
drugs in this concern is the correction of triglyceride and
elevation in HDLc level as the most of the drugs those
decreased the blood level of triglyceride also decreased the
level of HDLc [57]. High level of triglyceride and low level
of HDLc are independently related to morbidity and deaths
in diabetic subjects by the induction of to coronary heart
diseases [58, 59].
The extract is able to correct the diabetes-induced oxida-
tive injury which has been supported here by the elevation in
the activities of antioxidant enzymes and diminution in the
quantity of the products of the free radicals. This correction
may be due to the antidiabetic eﬃcacy of this extract that
preventsthereactiveoxygenspeciesgenerationbypreventing
glucose autooxidation and by glycation. Another possibility
is the presence of antioxidative types of neutraceutical like
ﬂavonoids in the above-mantioned extract.
From the above results, the antidiabetic potentiality of
aqueous-methanolic extract of S. mahagoni seed may be8 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Diagrammatic representation of diabetes induction by STZ (a) and the hypothetical ways the correction of diabetes-induced
metabolic disorders by aqueous-methanolic extract of S. mahagoni (b).
explained by two ways. One way may be the insulinotrophic
eﬀect of this extract that results correction in blood glucose
level, glycogen level in liver, the levels of serum lipid
proﬁle, and bio-sensors of protein metabolism as all of
these are under the control of serum insulin [60–62].
Another way may be the oxidative stress protection which
is developed mainly in metabolic tissues in diabetes. This
has been reﬂected here by the correction of antioxidant
enzyme activities that lowered the levels of end products
of free radicals. These antioxidant activities also protect
the metabolic enzymes in cells that resettled the cellular
homeostasis towards the normal level. The hypothetical
view for the corrective eﬀect of the plant extract on STZ-
induced diabetic hyperglycemia, hyperlipidemia, oxidative
injury, and high-protein catabolism may be expressed by the
diagram (Figures 9(a) and 9(b)). The speciﬁc bioingredi-
ent(s) or neutraceuticals present in the extract responsible
for such antidiabetic activity cannot be detected but this is
under our observation and would be focused from future
work in this line.Evidence-Based Complementary and Alternative Medicine 9
5. Conclusion
In conclusion, it may be stated that the aqueous-methanolic
extract of S. mahagoni seed may provide a new therapeutic
avenue against diabetes and diabetes-related complications.
Moreover, further work is necessary to search out the
active ingredients present in this extract having antidiabetic
eﬃcacy. Extensive research is currently taking place in India,
China, and Korea and in other countries in order to develop
potential herbal medicine to prevent metabolic diseases
including diabetes and its related complications.
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